Spinal muscular atrophy  community-oneSMAvoice

If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.

oneSMAvoice
  • Social Wall
  • Trusted Resources
    • EducationScientific literature & patient education texts
    • People & PlacesHealthcare providers, researchers, & advocates
    • Community CenterOnline groups, photo galleries, & blogs
    • News & MeetingsLatest announcements & gatherings
    • Videos & VisualsChannels, infographics, & slides
  • Clinical Trial Education
Global Search
Global Search
  • Social Wall Social Wall
  • Trusted Resources Trusted Resources
    • Trusted Resources Home

    • Education

      Scientific literature & patient education texts
    • People & Places

      Healthcare providers, researchers, & advocates
    • Community Center

      Online groups, photo galleries, & blogs
    • News & Meetings

      Latest announcements & gatherings
    • Videos & Visuals

      Channels, infographics, & slides
  • rareClinical Clinical Trial Education
  • my Account
Global Search
Log in
Register
en English
en Englishes Spanish
  • Register
  • Log in
en English
en Englishes Spanish

    contact us
    have a question, issue or just some feedback for us? we're here for you.



    DISCLAIMER

    The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
    compose your message

      *

      *


      message

      *

      message sent

      email sent successfully

      suggest a poll

      you must have an account to suggest polls.

      join now

      rareLife solutions 606 Post Road East #397
      Westport, CT 06880
      You are receiving this because you have an account on www.oneSMAvoice.com
      If you'd like to unsubscribe and stop receiving these emails click here

      Trusted Resources: News & Meetings

      Latest announcements and gatherings

      • Clinical Trial and Research
      • Business
      • People
      • Spotlight
      • Happenings
      Back to News & Meetings / Business

      Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMA


      Biogen announced it intends to initiate a global phase 3b study to investigate clinical outcomes and safety of a higher dose of Spinraza in patients with later onset spinal muscular atrophy previously treated with Evrysdi.

      “We believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with Evrysdi [risdiplam, Roche],” Maha Radhakrishnan, MD, chief medical officer at Biogen, said in a press release. “The ASCEND study seeks to understand if [Spinraza (nusinersen, Biogen)] may address that unmet medical need and will help inform the future of [spinal muscular atrophy (SMA)] treatment, with the hope of improving patients’ outcomes for the long term.”

      Data from prior studies suggested risdiplam exposure decreases as age and weight increase, with adults exhibiting an approximate 40% reduction in drug concentration compared with infants. Upon a patient reaching 20 kg, risdiplam’s dosing is capped at 5 mg.

       

      Biogen To Launch Study Of Higher Spinraza Dose In Patients With Later Onset SMA
      Source: https://www.healio.com/news/neurology/20210924/biogen-to-launch-study-of-higher-spinraza-dose-in-patients-with-later-onset-sma
      Share
      Discuss in Social Wall
      Share to rareTeam
      Bookmark

      Related Content

      • Community Center
        Every Day You Don’t Lose, You Are Winning
        Jennifer Summers, 35, is an optimistic, ...
      • Education
        Assessment of Cerebral Spinal Fluid Biomarkers and microRNA-Mediated Disease Mechanisms in Spinal Muscular Atrophy P...
        Cerebral spinal fluid (CSF) is a promisi...
      • News & Meetings
        Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor Problems
        Despite its well-reported benefits in mo...
      • Videos & Visuals
        Lunch & Learn: Gene Therapy for SMA
        https://www.youtube.com/watch?v=YFEMR1ZH...
      • Education
        Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
        Spinal muscular atrophy (SMA) is a neuro...
      • Videos & Visuals
        Your Guide to Spinal Muscular Atrophy
        https://simedhealth.com/sites/default/fi...
      • Education
        Spinal Muscular Atrophy Fact Sheet
        What is spinal muscular atrophy?Spinal m...

      send a message

      send to:
      subject:
      message:
      Back to Top
      edit tags:

      Reset password

      Enter Phone Number

      Enter the code

      Almost done!
      We just send a four digit code to your mobile number. Enter it here to login!
      Didn't receive the code?Re-send
      Or login in with your password instead

      password changed successfully!

      oneSMAvoice

      please log in with your email address and new password.

      your activation key expired

      oneSMAvoice

      this confirmation key has expired. please try to log in again or resend confirmation email.

      confirmation email sent

      oneSMAvoice

      a confirmation email has been sent to your inbox. click the link in the email to activate your account.
      can't find the email? be sure to check your spam folder.

      password reset email sent

      oneSMAvoice

      an email has been sent to you with a link to reset your password.
      can't find the email? be sure to check your spam folder.

      oneSMAvoice

      If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.

      your account is now activated!

      oneSMAvoice
      • register
      • log in

      Join the community

      You need an account to use this feature.

      Already have an account? Log in.

      I have read and understand the oneSMAvoice privacy policy and terms of use.

      Almost done!
      We just sent a four digit code to your mobile number. Enter it here to log in!
      Please Wait!!!
      Didn't receive the code? Re-send
      Or log in in with your password instead

      Log in

      You need to log in to use this feature.

      Don't have an account? Click here to register.

      you haven't confirmed your email address yet. resend confirmation email

      Forget your password? Reset here.
      Or log in with a one-time code
      or register with

      login with:


      Need to get in touch?

      Powered by

      In partnership with

      • About Us
      • FAQs
      • Legal & Privacy
      • Contact Us
      © 2023 rareLife solutions Inc.